Studies regarding the correlation (either positive or negative) among glucagon-like peptide 1 (GLP-1)-based medications including dipeptidyl peptidase 4 (DDP-4) inhibitors (the so-called “gliptins”) or anti-diabetics that target renal sodium-glucose cotransporter 2 (SGLT2 inhibitors or “gliflozins”) and cancer, cannot be considered as conclusive [19,20]. Here, GCG is linked to cancer.